Skip to main
LRMR
LRMR logo

LRMR Stock Forecast & Price Target

LRMR Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Larimar Therapeutics has demonstrated significant improvements in its lead product candidate, CTI-1601, with median frataxin (FXN) expression rising from 2.7 pg/ug at baseline to 13.44 pg/ug at six months, surpassing the levels observed in over 50% of healthy volunteers. Additionally, the company reported a median improvement in the modified Friedreich's Ataxia Rating Scale (mFARS) of -2.20 points, contrasting sharply with the predicted decline of +1.00 in the FACOMS natural history cohort over the same period. These positive clinical outcomes suggest a strong efficacy profile for CTI-1601, potentially bolstering investor confidence in Larimar Therapeutics's future performance.

Bears say

The financial outlook for Larimar Therapeutics is negatively impacted by a significant decline in their projected revenues, with FY29 estimates revised downward from $659 million to $407 million, indicating a potential shift in market expectations. Furthermore, the clinical data reflects concerning trends, as the median mFARS change of -2.20 points demonstrates a less favorable outcome compared to an observed improvement in the FACOMS natural history population, which recorded a +1.00 point change. These factors contribute to heightened skepticism regarding the efficacy of Larimar Therapeutics's lead product candidate, CTI-1601, and its potential market performance in treating Friedreich's ataxia.

LRMR has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Larimar Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Larimar Therapeutics Inc (LRMR) Forecast

Analysts have given LRMR a Buy based on their latest research and market trends.

According to 7 analysts, LRMR has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Larimar Therapeutics Inc (LRMR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.